Table 1.
Baseline characteristics by mAb treatment status for primary matched cohort.
| Untreated (N = 3663) | Sotrovimab-Treated (N = 1542) | |
|---|---|---|
| Age Groupa | ||
| 18-44 years | 997 (27.2%) | 387 (25.1%) |
| 45-64 years | 1219 (33.3%) | 492 (31.9%) |
| ≥65 years | 1447 (39.5%) | 663 (43.0%) |
| Female Gendera | 2231 (60.9%) | 916 (59.4%) |
| Race/Ethnicitya | ||
| Non-Hispanic White | 2974 (81.2%) | 1256 (81.5%) |
| Hispanic | 391 (10.7%) | 160 (10.4%) |
| Non-Hispanic Black | 95 (2.6%) | 41 (2.7%) |
| Other | 203 (5.5%) | 85 (5.5%) |
| Insurance Statusa | ||
| Private/Commercial | 1878 (51.3%) | 759 (49.2%) |
| Medicare | 1581 (43.2%) | 699 (45.3%) |
| Medicaid | 110 (3.0%) | 48 (3.1%) |
| None/Uninsured | 3 (0.1%) | 2 (0.1%) |
| Other/Unknown | 91 (2.5%) | 34 (2.2%) |
| Immunocompromised Statusa | ||
| None | 2148 (58.6%) | 902 (58.5%) |
| Mild | 679 (18.5%) | 275 (17.8%) |
| Moderate/Severe | 836 (22.8%) | 365 (23.7%) |
| Obesitya | 1119 (30.5%) | 483 (31.3%) |
| Number of Other Comorbid Conditionsa | ||
| None | 998 (27.0%) | 411 (26.7%) |
| One | 914 (25.0%) | 393 (25.5%) |
| Two or more | 1761 (48.1%) | 738 (47.9%) |
| Diabetes Mellitus | 716 (19.5%) | 371 (24.1%) |
| Cardiovascular Disease | 1116 (30.5%) | 446 (28.9%) |
| Pulmonary Disease | 1295 (35.4%) | 540 (35.0%) |
| Renal Disease | 446 (12.2%) | 268 (17.4%) |
| Hypertension | 1812 (49.5%) | 765 (49.6%) |
| Liver Disease | 488 (13.3%) | 235 (15.2%) |
| Number of Vaccinations Prior to SARS-CoV-2+a | ||
| 0 | 898 (24.5%) | 335 (21.7%) |
| 1 | 182 (5.0%) | 68 (4.4%) |
| 2 | 726 (19.8%) | 284 (18.4%) |
| 3+ | 1857 (50.7%) | 855 (55.4%) |
| Days to mAb Admin: mean (SD) | NA | 3.004 (1.967) |
| Time (Weeks)a | ||
| December 26 - January 1 | 704 (19.2%) | 258 (16.7%) |
| January 2 - January 8 | 353 (9.6%) | 106 (6.9%) |
| January 9 - January 15 | 382 (10.4%) | 127 (8.2%) |
| January 16 - January 22 | 500 (13.7%) | 170 (11.0%) |
| January 23 - January 29 | 393 (10.7%) | 128 (8.3%) |
| January 30 - February 5 | 442 (12.1%) | 188 (12.2%) |
| February 6 - February 12 | 291 (7.9%) | 167 (10.8%) |
| February 13 - February 19 | 211 (5.8%) | 112 (7.3%) |
| February 20 - February 26 | 181 (4.9%) | 107 (6.9%) |
| February 27 - March 5 | 116 (3.2%) | 102 (6.6%) |
| March 6 - March 10 | 90 (2.5%) | 77 (5.0%) |
a
Variables used in the propensity matching. Abbreviation: mAb, monoclonal antibody.